Close

Hospitalization

COVID-19 Hospitalization Surge Among US Children Spurs New Omicron Concerns

Within weeks, the Omicron variant has fueled thousands of new COVID-19 hospitalizations among U.S. children, raising new concerns about how the many unvaccinated Americans under the age of 18 will fare in the new surge. The seven-day-average number of daily hospitalizations for children between Dec. 21 and Dec. 27 is […]

Read More

Rivaroxaban Safely Cuts VTE Risk After COVID-19 Hospitalization: MICHELLE

Extended anticoagulation with low-dose rivaroxaban (Xarelto, Bayer/Janssen) after hospitalization for COVID-19 may reduce the risk of venous thromboembolism (VTE) without worsening the risk of bleeding in patients who had been considered high-risk for VTE, a multicenter randomized trial suggests. The primary efficacy outcome occurred in five (3%) patients assigned to rivaroxaban and 15 (9%) […]

Read More

Rivaroxaban Safely Cuts VTE Risk After COVID-19 Hospitalization: MICHELLE

Extended anticoagulation with low-dose rivaroxaban (Xarelto, Bayer/Janssen) after hospitalization for COVID-19 may reduce the risk of venous thromboembolism (VTE) without worsening the risk of bleeding in patients who had been considered high-risk for VTE, a multicenter randomized trial suggests. The primary efficacy outcome occurred in five (3%) patients assigned to rivaroxaban and 15 (9%) […]

Read More

Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021

Summary What is already known about this topic? Persons aged 12–18 years are eligible to receive COVID-19 vaccine. Currently, data are lacking on real-world vaccine effectiveness against COVID-19 hospitalization in adolescents. What is added by this report? Among hospitalized U.S. patients aged 12–18 years, vaccine effectiveness of 2 doses of […]

Read More

Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021

Summary What is already known about this topic? Persons aged 12–18 years are eligible to receive COVID-19 vaccine. Currently, data are lacking on real-world vaccine effectiveness against COVID-19 hospitalization in adolescents. What is added by this report? Among hospitalized U.S. patients aged 12–18 years, vaccine effectiveness of 2 doses of […]

Read More

Remdesivir Sharply Cuts COVID Hospitalization Risk, Gilead Says

Remdesivir (Veklury, Gilead) was found to reduce some COVID-19 patients’ risk of hospitalization by 87% in a phase 3 trial, the drug’s manufacturer announced Wednesday in a press release. The randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of a 3-day course of intravenous remdesivir in an analysis of 562 nonhospitalized […]

Read More

Among the unvaccinated, delta variant more than doubles risk of hospitalization

New research from England’s public health service has confirmed a suspicion spawned by bursting hospital wards across the United States: The delta variant of the coronavirus not only spreads 50% more readily than the alpha variant it rapidly overtook, it’s also making unvaccinated people sicker. Through most of April and May, […]

Read More

Hospitalization of Adolescents Aged 12–17 Years with Laboratory-Confirmed COVID-19 COVID-NET, 14 States, March 1, 2020 April 24, 2021

Summary What is already known about this topic? Most COVID-19–associated hospitalizations occur in adults, but severe disease occurs in all age groups, including adolescents aged 12–17 years. What is added by this report? COVID-19 adolescent hospitalization rates from COVID-NET peaked at 2.1 per 100,000 in early January 2021, declined to […]

Read More